Matching articles for "Hypogonadism"
Two New Oral Testosterone Products for Hypogonadism
The Medical Letter on Drugs and Therapeutics • October 31, 2022; (Issue 1662)
The FDA has approved two new oral formulations
of testosterone undecanoate — Kyzatrex (Marius)
and Tlando (Antares) — for treatment of males
with a deficiency of endogenous testosterone
due to...
The FDA has approved two new oral formulations
of testosterone undecanoate — Kyzatrex (Marius)
and Tlando (Antares) — for treatment of males
with a deficiency of endogenous testosterone
due to conditions such as Klinefelter syndrome,
orchiectomy, toxic damage from chemotherapy or
alcohol, or pituitary-hypothalamic injury caused
by tumors, trauma, or radiation. Jatenzo, another
oral testosterone undecanoate formulation, was
approved for the same indication in 2019. No
testosterone products are approved for treatment of
low testosterone levels due solely to aging.
Xyosted - A Testosterone Auto-Injector for Hypogonadism
The Medical Letter on Drugs and Therapeutics • March 11, 2019; (Issue 1567)
The FDA has approved an auto-injector formulation of
testosterone enanthate (Xyosted – Antares Pharma) for
once-weekly subcutaneous self-administration in adult
males with conditions associated with a...
The FDA has approved an auto-injector formulation of
testosterone enanthate (Xyosted – Antares Pharma) for
once-weekly subcutaneous self-administration in adult
males with conditions associated with a deficiency or
absence of endogenous testosterone. It is the first subcutaneous
formulation of testosterone to be approved by
the FDA. Xyosted is contraindicated for treatment of low
testosterone levels associated with aging.
Safety of Testosterone Replacement Therapy
The Medical Letter on Drugs and Therapeutics • March 14, 2016; (Issue 1490)
Three coordinated double-blind, placebo-controlled
clinical trials have evaluated the efficacy of one year of
testosterone replacement therapy in improving sexual
function, physical function, and vitality in...
Three coordinated double-blind, placebo-controlled
clinical trials have evaluated the efficacy of one year of
testosterone replacement therapy in improving sexual
function, physical function, and vitality in a total of
790 men ≥65 years old with moderately low serum
testosterone concentrations and symptoms suggesting
hypoandrogenism. Sexual function improved
modestly, and there appeared to be marginal benefits
in some areas of physical function and vitality as well.
The trials were not designed to evaluate the safety of
testosterone replacement therapy.
Testosterone Nasal Gel (Natesto) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • May 11, 2015; (Issue 1468)
The FDA has approved an intranasal gel formulation of
testosterone (Natesto – Trimel/Endo) for replacement
therapy in men with hypogonadism. Packaged in a
metered-dose pump, Natesto is the first...
The FDA has approved an intranasal gel formulation of
testosterone (Natesto – Trimel/Endo) for replacement
therapy in men with hypogonadism. Packaged in a
metered-dose pump, Natesto is the first intranasal
testosterone to become available in the US. Like other
testosterone products, it is classified as a schedule
III controlled substance. The FDA recently cautioned
against using testosterone to treat low testosterone
levels solely due to aging because the benefits and
safety of such use have not been established, and there
is a possible increased risk of myocardial infarction (MI)
and stroke.
A Long-Acting Depot Formulation of Testosterone (Aveed)
The Medical Letter on Drugs and Therapeutics • March 31, 2014; (Issue 1439)
The FDA has approved testosterone undecanoate (Aveed –
Endo), an injectable depot formulation, for use in men
with hypogonadism who require testosterone...
The FDA has approved testosterone undecanoate (Aveed –
Endo), an injectable depot formulation, for use in men
with hypogonadism who require testosterone replacement
therapy.
Testosterone Topical Solution (Axiron) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • July 11, 2011; (Issue 1368)
The Medical Letter recently reviewed a topical gel formulation
of testosterone (Fortesta) for treatment of
hypogonadism in men. A topical testosterone replacement
product for application to the axilla,...
The Medical Letter recently reviewed a topical gel formulation
of testosterone (Fortesta) for treatment of
hypogonadism in men. A topical testosterone replacement
product for application to the axilla, Axiron (Lilly)
solution, has now become available for the same indication.
This site of application presumably minimizes
the risk of transferring the drug to a family member or
sexual partner.
A New Testosterone Gel (Fortesta) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • April 18, 2011; (Issue 1362)
The FDA has approved Fortesta (Endo), a topical gel,
for testosterone replacement therapy in adult males
with hypogonadism. It is classified as a Schedule III
controlled substance. Table 1 lists some...
The FDA has approved Fortesta (Endo), a topical gel,
for testosterone replacement therapy in adult males
with hypogonadism. It is classified as a Schedule III
controlled substance. Table 1 lists some available
testosterone products, including 2 other gels.
Testim and Striant - Two New Testosterone Products
The Medical Letter on Drugs and Therapeutics • September 1, 2003; (Issue 1164)
Two new topical testosterone products, a 1% gel (Testim) and a buccal tablet (Striant), have been approved by the FDA for treatment of hypogonadism in men. This review briefly describes hypogonadism and its...
Two new topical testosterone products, a 1% gel (Testim) and a buccal tablet (Striant), have been approved by the FDA for treatment of hypogonadism in men. This review briefly describes hypogonadism and its causes and lists other available formulations of testosterone. For the new products, information on pharmocokinetics, adverse effects, and dosage and administration is provided, as well as a summary of clinical trial results. A dosage and cost table for topical testosterone products is also included. The conclusion summarizes the safety and effectiveness of the new drugs and discusses the potential risks and benefits of using testosterone replacement therapy in older men.
Testosterone Patches for Hypogonadism
The Medical Letter on Drugs and Therapeutics • May 24, 1996; (Issue 975)
Men with primary or secondary hypogonadism require lifelong androgen replacement to prevent osteoporosis and maintain normal muscle mass, erythropoiesis and sexual function (AM Matsumoto, Endocrinol Metab...
Men with primary or secondary hypogonadism require lifelong androgen replacement to prevent osteoporosis and maintain normal muscle mass, erythropoiesis and sexual function (AM Matsumoto, Endocrinol Metab Clin North Am, 23:857, 1994). Until recently, the standard treatment for male hypogonadism has been an intramuscular injection of a long-acting testosterone ester every two to three weeks, which leads to serum testosterone concentrations that are high for a few days, normal for a few days more, and then may be subnormal until the next dose. Two transdermal preparations of testosterone are now marketed in the USA. Testoderm (Alza) must be worn on the scrotum. Androderm (SmithKline Beecham), a newer patch, can be applied to the upper arms, thighs, back or abdomen. All androgens are controlled substances in the USA.